Integrating Single-cell and Bulk Transcriptomic Analyses to Develop a Cancer-associated Fibroblast-derived Biomarker for Predicting Prognosis and Therapeutic Response in Breast Cancer

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2024 Jan 18

PMID 38235137

Authors

Chunzhen Li

Lanjie Yang

Yunyan Zhang

Qianshan Hou

SiYi Wang

Shaoteng Lu

Yijie Tao

Wei Hu

Liyuan Zhao

Affiliations

Soon will be listed here.

Abstract

Background: Cancer-associated fibroblasts (CAFs) contribute to the progression and treatment of breast cancer (BRCA); however, risk signatures and molecular targets based on CAFs are limited. This study aims to identify novel CAF-related biomarkers to develop a risk signature for predicting the prognosis and therapeutic response of patients with BRCA.

Methods: CAF-related genes (CAFRGs) and a risk signature based on these genes were comprehensively analyzed using publicly available bulk and single-cell transcriptomic datasets. Modular genes identified from bulk sequencing data were intersected with CAF marker genes identified from single-cell analysis to obtain reliable CAFRGs. Signature CAFRGs were screened via Cox regression and least absolute shrinkage and selection operator (LASSO) analyses. Multiple patient cohorts were used to validate the prognosis and therapeutic responsiveness of high-risk patients stratified based on the CAFRG-based signature. In addition, the relationship between the CAFRG-based signature and clinicopathological factors, tumor immune landscape, functional pathways, chemotherapy sensitivity and immunotherapy sensitivity was examined. External datasets were used and sample experiments were performed to examine the expression pattern of MFAP4, a key CAFRG, in BRCA.

Results: Integrated analyses of single-cell and bulk transcriptomic data as well as prognostic screening revealed a total of 43 prognostic CAFRGs; of which, 14 genes (TLN2, SGCE, SDC1, SAV1, RUNX1, PDLIM4, OSMR, NT5E, MFAP4, IGFBP6, CTSO, COL12A1, CCDC8 and C1S) were identified as signature CAFRGs. The CAFRG-based risk signature exhibited favorable efficiency and accuracy in predicting survival outcomes and clinicopathological progression in multiple BRCA cohorts. Functional enrichment analysis suggested the involvement of the immune system, and the immune infiltration landscape significantly differed between the risk groups. Patients with high CAF-related risk scores (CAFRSs) exhibited tumor immunosuppression, enhanced cancer hallmarks and hyposensitivity to chemotherapy and immunotherapy. Five compounds were identified as promising therapeutic agents for high-CAFRS BRCA. External datasets and sample experiments validated the downregulation of MFAP4 and its strong correlation with CAFs in BRCA.

Conclusions: A novel CAF-derived gene signature with favorable predictive performance was developed in this study. This signature may be used to assess prognosis and guide individualized treatment for patients with BRCA.

Citing Articles

Enhancing immuno-oncology investigations through multidimensional decoding of tumor microenvironment with IOBR 2.0.

Zeng D, Fang Y, Qiu W, Luo P, Wang S, Shen R Cell Rep Methods. 2024; 4(12):100910.

PMID: 39626665 PMC: 11704618. DOI: 10.1016/j.crmeth.2024.100910.

Comprehensive single-cell and bulk transcriptomic analyses to develop an NK cell-derived gene signature for prognostic assessment and precision medicine in breast cancer.

Hou Q, Li C, Chong Y, Yin H, Guo Y, Yang L Front Immunol. 2024; 15:1460607.

PMID: 39507529 PMC: 11537931. DOI: 10.3389/fimmu.2024.1460607.

Siglec-G Suppresses CD8 T Cells Responses through Metabolic Rewiring and Can be Targeted to Enhance Tumor Immunotherapy.

Yin S, Li C, Shen X, Yu G, Cui L, Wu Y Adv Sci (Weinh). 2024; 11(45):e2403438.

PMID: 39373395 PMC: 11615767. DOI: 10.1002/advs.202403438.

A Novel Tumor-Associated Neutrophil-Related Risk Signature Based on Single-Cell and Bulk RNA-Sequencing Analyses Predicts the Prognosis and Immune Landscape of Breast Cancer.

Yin S, Li C, Zhang Y, Yin H, Fan Z, Ye X J Cancer. 2024; 15(17):5655-5671.

PMID: 39308692 PMC: 11414621. DOI: 10.7150/jca.100338.

Modulation of the tumor microenvironment and mechanism of immunotherapy-based drug resistance in breast cancer.

Kundu M, Butti R, Panda V, Malhotra D, Das S, Mitra T Mol Cancer. 2024; 23(1):92.

PMID: 38715072 PMC: 11075356. DOI: 10.1186/s12943-024-01990-4.

References

Szeto G, Finley S . Integrative Approaches to Cancer Immunotherapy. Trends Cancer. 2019; 5(7):400-410. PMC: 7467854. DOI: 10.1016/j.trecan.2019.05.010. View

Mao X, Xu J, Wang W, Liang C, Hua J, Liu J . Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021; 20(1):131. PMC: 8504100. DOI: 10.1186/s12943-021-01428-1. View

Xiang Z, Li J, Song S, Wang J, Cai W, Hu W . A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis. J Exp Clin Cancer Res. 2019; 38(1):314. PMC: 6637527. DOI: 10.1186/s13046-019-1318-5. View

Harbeck N, Gnant M . Breast cancer. Lancet. 2016; 389(10074):1134-1150. DOI: 10.1016/S0140-6736(16)31891-8. View

Zheng S, Liang J, Tang Y, Xie J, Zou Y, Yang A . Dissecting the role of cancer-associated fibroblast-derived biglycan as a potential therapeutic target in immunotherapy resistance: A tumor bulk and single-cell transcriptomic study. Clin Transl Med. 2023; 13(2):e1189. PMC: 9920016. DOI: 10.1002/ctm2.1189. View

Geeleher P, Cox N, Huang R . Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014; 15(3):R47. PMC: 4054092. DOI: 10.1186/gb-2014-15-3-r47. View

Jia Y, Shi H, Cao Y, Feng W, Li M, Li X . PDZ and LIM domain protein 4 suppresses the growth and invasion of ovarian cancer cells via inactivation of STAT3 signaling. Life Sci. 2019; 233:116715. DOI: 10.1016/j.lfs.2019.116715. View

Luo Y, Tian W, Lu X, Zhang C, Xie J, Deng X . Prognosis stratification in breast cancer and characterization of immunosuppressive microenvironment through a pyrimidine metabolism-related signature. Front Immunol. 2022; 13:1056680. PMC: 9745154. DOI: 10.3389/fimmu.2022.1056680. View

Araujo A, Abaurrea A, Azcoaga P, Lopez-Velazco J, Manzano S, Rodriguez J . Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment. J Clin Invest. 2022; 132(7). PMC: 8970678. DOI: 10.1172/JCI148667. View

10.

Tang Z, Yang Y, Zhang Q, Liang T . Epigenetic dysregulation-mediated COL12A1 upregulation predicts worse outcome in intrahepatic cholangiocarcinoma patients. Clin Epigenetics. 2023; 15(1):13. PMC: 9875497. DOI: 10.1186/s13148-022-01413-5. View

11.

Baxevanis C, Fortis S, Perez S . The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies. Semin Cancer Biol. 2019; 72:76-89. DOI: 10.1016/j.semcancer.2019.12.018. View

12.

Szekely B, Bossuyt V, Li X, Wali V, Patwardhan G, Frederick C . Immunological differences between primary and metastatic breast cancer. Ann Oncol. 2018; 29(11):2232-2239. DOI: 10.1093/annonc/mdy399. View

13.

Riaz N, Havel J, Makarov V, Desrichard A, Urba W, Sims J . Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab. Cell. 2017; 171(4):934-949.e16. PMC: 5685550. DOI: 10.1016/j.cell.2017.09.028. View

14.

Uhlen M, Fagerberg L, Hallstrom B, Lindskog C, Oksvold P, Mardinoglu A . Proteomics. Tissue-based map of the human proteome. Science. 2015; 347(6220):1260419. DOI: 10.1126/science.1260419. View

15.

Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z . GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017; 45(W1):W98-W102. PMC: 5570223. DOI: 10.1093/nar/gkx247. View

16.

Qiao W, Liu H, Guo W, Li P, Deng M . Prognostic and clinical significance of syndecan-1 expression in breast cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2019; 45(7):1132-1137. DOI: 10.1016/j.ejso.2018.12.019. View

17.

Pure E, Blomberg R . Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics. Oncogene. 2018; 37(32):4343-4357. PMC: 6092565. DOI: 10.1038/s41388-018-0275-3. View

18.

Shi G, Chapman H, Bhairi S, DeLeeuw C, Reddy V, Weiss S . Molecular cloning of human cathepsin O, a novel endoproteinase and homologue of rabbit OC2. FEBS Lett. 1995; 357(2):129-34. DOI: 10.1016/0014-5793(94)01349-6. View

19.

Orimo A, Gupta P, Sgroi D, Arenzana-Seisdedos F, Delaunay T, Naeem R . Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005; 121(3):335-48. DOI: 10.1016/j.cell.2005.02.034. View

20.

Lee B, Hogg E, Below C, Kononov A, Blanco-Gomez A, Heider F . Heterocellular OSM-OSMR signalling reprograms fibroblasts to promote pancreatic cancer growth and metastasis. Nat Commun. 2021; 12(1):7336. PMC: 8683436. DOI: 10.1038/s41467-021-27607-8. View